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Abstract 
Microphthalmia, coloboma and cataract are part of a spectrum of developmental eye 
disorders in humans affecting ~12 per 100,000 live births. Currently, variants in over 100 
genes are known to underlie these conditions. However, at least 40% of affected individuals 
remain without a clinical genetic diagnosis, suggesting variants in additional genes may be 
responsible. Calpain 15 (CAPN15) is an intracellular cysteine protease belonging to the non-
classical Small Optic Lobe (SOL) family of calpains, an important class of developmental 
proteins, as yet uncharacterised in vertebrates. We identified five individuals with 
microphthalmia and/or coloboma from four independent families carrying homozygous or 
compound heterozygous predicted damaging variants in CAPN15. Several individuals had 
additional phenotypes including growth deficits, developmental delay and hearing loss. We 
generated Capn15 knockout mice that exhibited similar severe developmental eye defects, 
including anophthalmia, microphthalmia, and cataract, and diminished growth. We 
demonstrate widespread Capn15 expression throughout the brain and central nervous system, 
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strongest during early development, and decreasing postnatally. Together, these findings 
demonstrate a critical role of CAPN15 in vertebrate developmental eye disorders, and may 
signify a new developmental pathway. 
Introduction 
Developmental eye anomalies, including anophthalmia (absent eye), microphthalmia (small 
eye) and coloboma (disruption of the optic fissure closure), collectively known as AMC, are a 
genetically heterogeneous group of disorders affecting between 11.9 and 30 per 100,000 live 
births(1). Single gene alterations can underlie these conditions, the most frequent being in 
SOX2(2). To date, ~100 genes have been consistently associated with these phenotypes and 
are included in standard structural eye disorders diagnostic panels 
(https://panelapp.genomicsengland.co.uk/panels/509/). Data for congenital cataracts are 
similar, with an estimated prevalence of 1.91 to 4.24 per 10,000 children (3) and nearly 100 
genes considered diagnostic (https://panelapp.genomicsengland.co.uk/panels/230/). There is a 
degree of genetic overlap in the underlying causes of AMC and cataract, as seen with variants 
in GJA8 (4). However, at least 40% of individuals with AMC (depending on phenotype) 
remain without a genetic diagnosis (2, 5), indicating that additional unidentified genetic 
factors contribute to these conditions.  
Calpains are intracellular cysteine proteases(6) with important roles in development. There 
are four conserved families: Classical, PalB, Transformer (Tra), and Small Optic Lobe 
(SOL), with ‘Classical’ being the best characterized. All calpain isoforms have a conserved 
catalytic domain and each family is characterized by unique domains: a C-terminal penta-EF 
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hand domain in Classical calpains; a C-terminal C2 domain in Tra calpains; an N-terminal 
MIT domain and an additional C-terminal C2-like domain in PalB calpains, and an N-
terminal zinc finger domain that binds polyubiquitin(7) and a C-terminal SOL homology 
domain (SOLH) in SOL calpains(8, 9). 
Embryonic mice with a homozygous disruption of the murine Classical calpain small subunit 
gene Capn4 (causing disruption of the activities of Classical calpains Capn1 and Capn2) die 
midgestation, displaying defects in the cardiovascular system, hemorrhage, and accumulation 
of erythroid progenitors(10). Furthermore, pre-implantation embryonic lethality between the 
morula and blastocyst stage is observed in mice with a homozygous Capn2 deletion (11). 
Tra-3 (Transformer 3) calpain was first discovered in the nematode C. elegans, as a sex 
determination gene(12). Later, studies suggested that Tra-3 cleaves Tra-2, which then 
interacts with transcription factor Tra-1 both directly and indirectly to promote female 
development(13, 14). In addition, C. elegans with a single nucleotide polymorphism in Tra-3 
displayed a smaller body size when animals were grown at low temperature(15). In humans, 
variants in the orthologue of the Tra calpain (CAPN5) that hyperactivate its protease activity 
are associated with inflammatory vitreoretinopathy, hearing loss and developmental delay 
(16).  
An atypical calpain, CAPN15 (also known as SOLH or SOL calpain) is located on 
chromosome 16p13.3(17), a region previously implicated in inherited cataracts with 
microphthalmia(18). It was first characterized in the fruit fly Drosophila(19, 20), where loss 
of SOL calpain leads to a 50% reduction in the volume of the optic lobes due to degeneration 
and absence of certain classes of columnar neurons(20). In Aplysia, the orthologue of 
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CAPN15 is required for the induction of long-term plasticity implicated in non-associative 
memory, but not the long-term plasticity implicated in associative memory (21, 22).  
Using whole exome sequencing (WES) we identified five individuals from four independent 
families with likely pathogenic homozygous or compound heterozygous variants in CAPN15, 
displaying microphthalmia and/or coloboma plus additional phenotypes including growth 
delay. To characterize the role of CAPN15 in vertebrates, we generated a Capn15 knockout 
mouse. Capn15(-/-) mice displayed developmental eye anomalies including anophthalmia,
microphthalmia and cataract, as well as reduced body weight similar to our affected 
individuals. Our data shows that CAPN15 plays a critical role in eye development and growth 
in vertebrates. It is the first intracellular protease linked to AMC, indicating a new pathway 
and is an important gene to include on diagnostic gene panels for developmental eye 
disorders and cataract. 
Results  
Identification of five individuals with CAPN15 mutations and eye anomalies 
WES of 55 individuals with developmental eye disorders from a UK cohort (Supplemental 
Methods) identified one individual with unilateral microphthalmia and bilateral coloboma 
with a previously unreported homozygous missense variant in CAPN15 exon 13 
(NM_005632.2:c.2905G>A; NP_005623.1:p.(Gly969Ser); chr16:602863 [hg19]) (Individual 
1) (Figure 1A). Subsequently, four additional individuals with AMC spectrum disorders and
biallelic CAPN15 variants from three independent families were identified by WES. 
Individual 2, recruited to the Deciphering Developmental Disorders (DDD) project, was 
identified with compound heterozygous CAPN15 variants. The first variant was a paternally 
inherited missense variant in exon 8 (NM_005632:c.2159C>T; NP_005623.1:p.(Ser720Phe); 
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chr16:601394 [hg19]), absent from the gnomAD database 
(http://gnomad.broadinstitute.org/)(23). The second variant was a rare maternally inherited 
missense variant in exon 10 (rs762523863; NM_005632:c.2398C>T; 
NP_005623.1:p.(Arg800Trp); gnomAD minor allele frequency = 0.00001986) (chr16:602103 
[hg19]) (Figure 1B). Individual 3 carries a homozygous missense variant in CAPN15 exon 13 
(NM_005632.3:c.3083G>A; p.(Arg1028Lys); chr16: 603041 [hg19]) absent from the 
gnomAD database(23) (Figure 1C). Finally, individuals 4 and 5, siblings and offspring of 
distantly related parents, were ascertained through a Canadian cohort of 51 patients 
presenting with anomalies, with or without neurodevelopmental disorders (24). They harbour 
a homozygous missense variant in CAPN15 exon 6 (NM_005632.3:c.1838C>T; 
NP_005623.1:p.(Ser613Leu); chr16:599467 [hg19]) (Figure 1D). This variant is extremely 
rare, reported in only 3 individuals on the gnomAD database (minor allele frequency 
0.00001421), with no individuals with homozygosity for this variant observed. All five 
variants are predicted damaging by SIFT(25) and PolyPhen-2(26) and were validated by 
Sanger sequencing. In each case, the identified variants were inherited from asymptomatic 
heterozygous parents with no family history of eye anomalies. The siblings of Individual 1 
were found to be asymptomatic heterozygous carriers. No genotyping data is available for the 
unaffected sibling of Individuals 4 and 5. The segregation of disease with biallelic CAPN15 
variants in these five families confirms a recessive pattern of inheritance. No other likely 
pathogenic variants in known AMC genes were identified in these individuals by WES. 
Detailed phenotypic descriptions of each individual are provided in Table 1, Figure 2 and the 
Supplemental Results. All five affected individuals presented with AMC spectrum disorders; 
two individuals (1 and 2) had microphthalmia, four had coloboma (1, 3, 4, and 5), and 
Individual 1 also had a unilateral lens opacity (cataract). Interestingly, some individuals 
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showed additional delay in growth and development. Three individuals showed delayed 
growth, including short stature (1, 2, and 4), low weight (1 and 2), reduced head 
circumference (1 and 2) and clinical microcephaly affecting Individual 4. Furthermore, 
Individuals 2, 4 and 5 presented with developmental delay, in addition to cognitive delay (2) 
and autism (2 and 5). Finally, three individuals (2, 4 and 5) were diagnosed with hearing loss 
and both Individuals 2 and 4 had simple external ear features. It is also interesting to note the 
presence of multiple miscarriages in Family 1.  
As the c.2905G>A (Individual 1) and c.3083G>A (Individual 3) variants affect the first and 
last nucleotides of CAPN15 exon 13, respectively, we investigated their impact on splicing. 
For c.2905G>A we generated cDNA from blood samples from Individual 1 and their parents. 
However, PCR and Sanger sequencing across exons 11-14 revealed no alteration in splicing 
(data available on request). Similarly, for Individual 3 we observed no impact on splicing 
after performing RTPCR on RNA extracted from LCLs derived from this patient (data 
available on request). 
Within CAPN15, all five variants are located within the C-terminal portion of the protein and 
affect amino acids conserved across multiple vertebrate species (Figure 3). However, only 
p.(Ser613Leu) (Individuals 4 and 5) and p.(Ser720Phe) (Individual 2) are located within an 
annotated region of the protein, both lying within the Calpain catalytic domain. As no 3D 
structure for CAPN15 is available, we used I-TASSER (27-29) to generate a predicted 
structure. Site Directed Mutator (SDM; http://marid.bioc.cam.ac.uk/sdm2/prediction) was 
applied to this model to predict the impact of the variants on CAPN15 stability (Table 2). 
This indicated that p.(Gly969Ser) and p.(Arg1028Lys) may decrease protein stability (G = 
-3.27 and -1.15, respectively), whereas p.(Ser613Leu) is predicted to increase stability (G
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= 1.85). Interestingly, both of the mutations predicted to decrease CAPN15 stability are in the 
highly conserved SOLH domain that is present only in SOL calpains and whose structure and 
function is unknown. 
Capn15(-/-) mice have anophthalmia, microphthalmia and cataract
The protein encoded by the human CAPN15 gene (NP_005623.1) has 87.4% identity/90.9% 
similarity to the mouse orthologue NP_001334263 using EMBOSS Needle (30). Mouse 
embryonic stem cells with a lacZ-Neo cassette inserted into the Capn15 locus were obtained 
from the International Mouse Phenotyping Consortium (IMPC)(31) and used to generate 
Capn15 knockout mice (Supplemental Figure 1A). Disruption of Capn15 was confirmed by 
Western blotting of brain homogenates using an antibody raised against the C-terminal of the 
protein (Supplemental Figure 1B).   
In a cross of Capn15 heterozygous mice, the incidence of Capn15(-/-) pups was 12%,
significantly lower than the expected 25% (12%, p=1.28e-5, Chi Square test; WT n=52,
Capn15+/- n=155, Capn15-/- n=29). This indicates that homozygous loss of the gene results in
decreased viability, and is of further interest given the presence of multiple miscarriages in 
Family 1. Furthermore, Capn15(-/-) mice that were successfully weaned weighed 11% (+/-3%
SEM) less than their littermate WT or heterozygous mice (p=0.003 and p=0.0006, 
respectively. Student’s t-test; WT n=45, Capn15+/- n=71, Capn15-/- n=18), recapitulating the
delayed growth and development in several of our affected individuals (Figure 4A). Most 
significantly, homozygous Capn15 KO mice displayed a range of developmental eye 
disorders overlapping those observed in the 5 affected individuals with biallelic CAPN15 
variants. These included anophthalmia (18%), microphthalmia (26%) and cataract (31%) 
(Figure 4B-E). Less than 6% of heterozygous mice overall displayed developmental eye 
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disorders (anophthalmia 1%, microphthalmia 2%, and cataract in 2%). No significant 
difference was observed between the left and right eyes of adult Capn15 KO mice (>12 
weeks of age) (p=0.15) and there was no preference for bilateral or unilateral presentation. 
Therefore, after pooling left and right eyes, the presence of these phenotypes was 
significantly increased in Capn15 KO mice compared to heterozygous or WT mice 
(***p<0.0001; WT n=30, Capn15+/- n=160, Capn15-/- n=90 including offspring from parents
who were both Capn15-/-; Figure 4F). This difference in eye phenotype was present in mice at
6 and 12 weeks of age, suggesting that these anomalies were the result of aberrant 
development.   
Capn15 is highly expressed in the brain and eye 
To investigate the role of Capn15 in the brain during development, lacZ expression was 
examined in Capn15(lacZ-Neo) heterozygous mice. X-gal staining of sagittal sections of E12
embryos showed that Capn15 was primarily expressed in the outer layer of the central 
nervous system, in particular the mantle zone of the pallium and subpallium (forebrain), and 
the mantle zone of the rhombomere (hindbrain) (Figure 5A). At E18 Capn15 was expressed 
widely in the nervous system with high levels in the subventricular zone, immediately next to 
the ventricular zone. Expression was strongest in the deep cortical layer of the cerebral 
cortex, and neuroepithelium layer in the hippocampus, but not the pyramidal layer. By P3, 
Capn15 was ubiquitously expressed in the brain from the olfactory bulb to the cerebellum 
and also within the retina, particularly in the ganglion cell layer (Figure 5C-D). To further 
explore the pattern of expression over time, Capn15 protein expression in the rat brain was 
examined over time using immunoblotting. Here, expression was found to be highest during 
embryonic development (E14-E18 brains), decreasing significantly after birth (P0-adult) 
(Figure 5E, F).  
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Discussion 
Our data demonstrate the importance of the protease CAPN15 in mammalian eye and brain 
development. We identified likely pathogenic recessively inherited variants in five 
individuals with AMC and/or cataract and additional phenotypes including delayed growth 
and development. These phenotypes were recapitulated in a mouse model, with further data 
supporting expression of the gene during brain development.   
Our cases showed microphthalmia and/or coloboma, while 18% of knockout mice had the 
more severe anophthalmia. The milder phenotypic range displayed in the humans may be 
explained by all five variants being missense. These variants could impact protein function by 
destabilising protein structure, affecting the calpain catalytic activity, or its regulation by the 
SOLH domain. This is likely to be less damaging to overall function than the total loss of the 
gene in the mouse knockout. This may also account for the presence of AMC phenotypes at 
low frequency in heterozygous mice, which were not detected in humans heterozygous for 
the missense variants. Alternatively, it may reflect the small sample group of humans or 
interspecies variation. However, given the lack of a functional assay for CAPN15, it is 
difficult to determine whether the variability between mouse and human phenotypes and/or 
amongst the individuals carrying distinct missense changes is due to different effects of these 
variants on the protein. The penetrance of the eye phenotype in the mouse was also variable, 
even with a complete knockout, suggesting a complex relationship between the loss of 
CAPN15 and the eye phenotype. Therefore, screening of additional individuals with AMC 
would help to determine both the full phenotypic range associated with variants in this gene, 
as well as potential genotype-phenotype correlations. Furthermore, only Individual 1 had 
cataract, while 31% of mice had this phenotype. This may reflect ascertainment bias, as none 
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of the participants or cohorts included in this study was recruited on the basis of this 
phenotype. However, recent reports show that variants in GJA8, a gene associated with 
isolated cataract, are also a significant cause of microphthalmia, accounting for over 1% of 
cases of AMC in large cohorts (4). 
Developmental delay and hearing loss were present in three individuals with CAPN15 
variants. Our data shows strong embryonic expression of Capn15 in the brain, suggesting that 
it is important in neurodevelopment. Therefore, the CAPN15 variants may underlie these 
phenotypes as well as eye anomalies. Similarly, growth delay was observed in three 
individuals and the Capn15-/- mice also exhibited a significant growth deficit.
There is little known about the function of the SOL calpain family, of which CAPN15 is the 
sole human member. This family diverged from other calpain families before the origin of 
metazoans and is conserved in all metazoans, suggesting a fundamental role for the protein 
(9). Two of the identified variants are in conserved residues in the calpain catalytic domain 
present in all members of the calpain family, while a third variant lies adjacent to it. 
However, while the N-terminal of the SOL calpain has been shown to bind to poly-
ubiquitin(7), there have been no functional studies on the calpain or SOLH domain of this 
family of genes. In Drosophila, the large loss of neurons in the optic lobe was thought to be 
due to degeneration(20), but a role for Capn15 in early differentiation during development 
was not excluded. In Aplysia, SOL calpain is important for the induction of plasticity 
associated with non-associative learning(21), perhaps due to cleavage of Protein Kinase Cs 
(PKCs) into persistently active Protein Kinase Ms (PKMs)(7, 32). Further investigation of 
how Capn15 performs these functions may also shed light on its role during eye 
development. Furthermore, as other calpains function to regulate transcription through 
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regulated cleavage of transcription factors (33), and since many genes underlying ocular 
anomalies are transcription factors(2), investigation of the role CAPN15 plays in early 
developmental transcriptional pathways may also prove a valuable avenue of research.  
Together, our data meet criteria for inclusion of CAPN15 in clinical genetic diagnostic testing 
for AMC according to both the Clinical Genome Resource (ClinGen) 
(www.clinicalgenome.org)(34, 35) and Genomics England PanelApp 
(https://panelapp.genomicsengland.co.uk/#!Guidelines). Therefore, these data will contribute 
to improved care for AMC patients and their families. 
Conclusions 
We demonstrate for the first time the importance of CAPN15 in mammalian eye 
development, identifying likely pathogenic variants in five individuals with AMC from four 
families, supported by a mouse KO model and embryonic expression studies. These findings 
translate to clinical benefit by adding a new gene to clinical diagnostic testing, and potentially 
a new pathway in the increasingly complex network involved in human eye development.   
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Materials and Methods  
Ethics approval and consent to participate 
The UK cohort of 316 individuals with ocular anomalies was recruited as part of a national 
‘Genetics of Eye and Brain anomalies’ study (REC 04/Q0104/129). Informed consent was 
obtained according to the tenets of the Declaration of Helsinki. Individual 2 was recruited 
into the Deciphering Developmental Disorders (DDD) Study, which has UK Research Ethics 
Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 
granted by the Republic of Ireland REC). For individual 3, informed written consent was 
obtained from all participants under an IRB approved protocol (KFSHRC RAC# 2070023).  
Individuals 4 and 5 are members of a Canadian study approved by the institutional ethics 
review board of Université de Sherbrooke (project 12–167). All participants or their legal 
guardians provided written consent. All studies on mice were approved by the Montreal 
Neurological Institute/McGill University Animal care and use committee protocol 2009–
5784 
Capn15 antibody 
Polyclonal antibodies were raised in rabbits against the carboxy terminal of Capn15 using 
the following epitope: CDVAGLHGPRPL. A cysteine residue was added to the N-terminal 
of the peptide to enhance coupling. Peptides were coupled to KLH-maleimide and 
SulfoLink coupling resin (Thermo Fisher Scientific) according to manufacturer’s 
instruction. After conjugation to KLH-maleimide, rabbits were injected and after four 
boosts the final serum was affinity purified on SulfoLink columns as previously 
described(36). 
Generation of a Capn15 KO mouse 
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We obtained embryonic stem cells with a lacZ-Neo cassette inserted into the mouse Capn15 
locus from the International Mouse Phenotyping Consortium (IMPC)(31). The strategy used 
by the consortium was to insert a cassette that provides a strong exon entry site coupled with 
a stop codon, with lacZ produced from internal ribosome entry site translation (31, 37). To 
remove this cassette, these mice were bred with mice that contain flippase (FLP) recombinase 
that recognizes a pair of FLP recombinase target (FRT) sequences that flank the genomic 
region containing this cassette leaving lox sites surrounding the calpain catalytic domain 
exons 4-6 (based on NCBI reference sequence NM_001347334.1). These mice were then 
bred against mice expressing germline Cre recombinase to remove the floxed exons and 
generate a KO line (Supplemental Figure 1). 
Dissections 
Adult mice were transcardially perfused with ice-cold phosphate-buffered saline (PBS) 
followed by 4% (wt/vol) ice-cold paraformaldehyde (PFA) in PBS. Brains were post-fixed 
in 4% PFA for 45min at 4oC, rinsed in PBS, and cryoprotected in 30% sucrose/PBS
overnight at 4oC. The following day, brains were embedded in Tissue-PlusTM O.C.T.
compound (Fisher Healthcare) and flash frozen in 2-methylbutane chilled in dry ice. The 
brains were kept at −80°C until further use. 
X-gal staining
Sections of 20μm were incubated overnight at 37°C in solution containing 80 mM 
Na2HPO4, 20 mM NaH2PO4, 2 mM MgSO4, 5 mM K₃[Fe(CN)₆], 5 mM K4[Fe(CN)₆], 0.2% 
NP-40, 0.1% sodium deoxycholate, and 1.5 mg/ml X-gal. Sections were rinsed in PBS, 
washed in ethanol (50% for 1min, 70% for 1min, 95% for 1min and 100% for 2X1min), 
cleared in xylene, and mounted with Permount (Thermo Fisher Scientific). 
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Western blotting 
Embryonic brains were homogenized manually in lysis buffer containing 25 mM Tris-HCl 
(pH 7.4), 150 mM NaCl, 6 mM MgCl2, 2 mM EDTA, 1.25% NP-40, 0.125% SDS, 25 mM 
NaF, 2 mM Na4P2O7, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride 
(PMSF), 20 mg/ml leupeptin, and 4 mg/ml aprotinin. Before loading, 5X sample buffer 
was added to the lysate and samples were incubated at 95oC for 5min. Proteins were
resolved by SDS-PAGE on Bis-Tris gel and transferred to nitrocellulose membrane (Bio-
Rad). The blots were blocked in TBST (TBS + 0.1% Tween) containing 4% skim milk for 
30min at room temperature and then incubated with primary antibodies overnight at 4oC.
After washing 3 times with TBST, the blots were incubated with HRP-conjugated secondary 
antibodies for 1 hour at RT, and washed again 3 times in TBST. The Western Lightning Plus- 
ECL kit (NEL103001EA; PerkinElmer LLC Waltham, MA USA) was used as per 
manufacturer’s instructions to detect protein bands. The primary antibody used was 
homemade rabbit anti-Capn15 antibody (1:1000) raised against the C-terminus of Capn15. 
The secondary antibody was horseradish peroxidase-conjugated goat anti-rabbit secondary 
antibody (1:5000). Antibodies were diluted in Tris buffered saline with Tween containing 4% 
skim milk powder.  
Eye phenotype quantification 
Mice eyes were examined and grouped as follows: seems normal, obvious cataract, small eye 
and no eye. This categorisation was performed for both eyes of each mouse. The analysis was 
performed without the knowledge of the genotype of the mice.  
Quantification of immunoblotting 
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Immunoblots were scanned and imaged using the public domain Image J program developed 
at the U.S. National Institute of Health (https://imagej.nih.gov/ij/). We calibrated our data 
with the uncalibrated optical density feature of NIH image, which transforms the data using 
the formula        , where x is the pixel value (0–254). We used the Ponceau image for 
each gel to normalize the amount of SOL calpain in brains at different ages to the amount of 
SOL calpain in E12-E14 brains run on the same gel. 
Whole Exome Sequencing 
A UK cohort of 316 individuals with ocular anomalies, principally AMC, was recruited as 
part of a national ‘Genetics of Eye and Brain anomalies’ study (REC 04/Q0104/129). 
Informed consent was obtained according to the tenets of the Declaration of Helsinki. 
Patients were screened by indication in known AMC genes. Fifty-five individuals from the 
cohort were screened by whole exome sequencing (WES) as described previously(38, 39). 
Individual 2 was recruited into the Deciphering Developmental Disorders (DDD) Study, 
which has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge 
South REC, and GEN/284/12 granted by the Republic of Ireland REC).  
For individual 3, WES was performed as previously described (40).  Sanger sequencing and 
segregation analysis were completed. Informed written consent was obtained from all 
participants under an IRB approved protocol (KFSHRC RAC# 2070023).  
Individuals 4 and 5 are siblings who were identified through whole-exome sequencing of a 
Canadian cohort of 51 patients presenting dysmorphisms with or without neurodevelopmental 
disorders (24). 
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The following primers were used for sequencing: For Individual 1: Forward Primer 
CCATCATCCTGCTCACCGA and Reverse Primer GGCACGCTATCCTGGGTAC; For 
Individual 2 Exon 8: Forward Primer GCAACATGAAGGTGGACGAT and Reverse Primer 
AGCTGCCGTTCCAGGAGAAA; For Individual 2 Exon 10: Forward Primer 
GGAGGGCTTCCTATTATAGG and Reverse Primer AACACCAGGATGCACAGGTC and 
For Individual 3: Forward Primer GCAGGGGTCCCGAGA and Reverse Primer 
CAGACCGGCGACCTCT. 
cDNA and splicing studies 
Blood samples were collected from Individual 1 and her parents, RNA was extracted using a 
RNeasy Mini kit (Qiagen) and cDNA generated using a high capacity reverse transcriptase 
kit (Applied Biosystems). To examine the impact of the variant on splicing, forward and 
reverse PCR primers were designed mapping to exons 11 and 14, respectively (Forward: 
GTCAAGAAGTTCGTCAGCTG, Reverse: CTGTCCAGTCACTGAGGAAG). 
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Figure Legends 
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Figure 1. Pedigrees of the five Individuals with CAPN15 variants. Chromatograms of 
Sanger sequencing validation of the variants in affected individuals shown. Position of 
variant indicated in red. Note that sequencing for Individual 3 was performed from cDNA. 
(A) Individual 1 (B) Individual 2 (C) Individual 3 (D) Individuals 4 and 5.
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Figure 2. Phenotypes of Individuals 1, 3 and 4. (A) Right iris and chorioretinal coloboma, 
and left mild microphthalmia with an iris and chorioretinal coloboma involving the disc in 
Individual 1. (B, C) Inferonasal chorioretinal coloboma (B) and iris coloboma of the right eye 
(C) in Individual 3. (D) Bilateral iris and chorioretinal coloboma (more prominent in the left
eye), and dysmorphic features including left ptosis, left simple ear, and prominent columella 
in Individual 4. 
Figure 3. Schematic of CAPN15 showing the location of the variants identified in 
Individuals 1-5. Zinc fingers shown in red, the calpain catalytic domain in blue and the 
SOLH domain in green. The conservation of the affected amino acids in human, mouse, 
chicken, Xenopus and zebrafish is indicated. 
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Figure 4. Capn15 KO mice display growth and eye anomalies (A) Mean weights of 
Capn15 KO and Capn15 heterozygous mice after weaning normalized to the mean weight of 
WT mice. Error bars represent SEM. (B-E) Representative photographs of the eye 
phenotypes of Capn15 KO mice; normal (B), anophthalmia (C), microphthalmia (D) and 
cataract (E). (F) Comparison of the percentage of eye anomalies in WT, Capn15 
28 
heterozygous and Capn15 KO mice at more than 12 weeks of age. ** = p=0.003, *** = 
p=0.0006. 
Figure 5. Capn15 is enriched in rodent brain and eyes during early development. (A-D) 
X-gal staining of sections from E12, E18 and P3 Capn15(lacZ-Neo) heterozygous mice. Scale
29 
bar is 200μm.  (A) Sagittal section of whole embryo at E12 showing Capn15 expression in 
the mantle zones of the pallium, subpallium, and rhombomere. (B) Coronal section of the 
brain at E18 showing expression in the cerebral cortex, hippocampus. (C) Coronal section of 
the brain at P3 showing generalised expression, including the hippocampus. (D) Sagittal 
section of the eye at P3, highlighting expression in the ganglion cells of the retina. (E) 
Western blots using protein extracts from rat brains at E14, E18, P0, P30 and P≥60 showing 
decreasing Capn15 expression with increasing age. Experiment was performed in triplicate. 
(F) Quantification of Capn15 expression in rat brain. Capn15 expression was normalized to
E12-E14 brains; E12-E14 n=3, E16-E18 n=4, P0-P5 n=4, P30 n=2, and P≥60 n=3. Error bars 
represent SEM. Abbreviations: C (cortex), G (ganglion cell layer), Hi (hippocampus), Hy 
(hypothalamus), MZP (mantle zone of pallium), MZR (mantle zone of rhombomere), MZS 
(mantle zone of subpallium), P (photoreceptor cell layer). 
Table 1: Phenotypes of the five human individuals identified carrying homozygous or 
compound heterozygous CAPN15 variants. Individuals 4 and 5 are siblings. y (years). 
Individual 1 2 3 4 5 
Variant p.(Gly969Ser) p.(Ser720Phe) 
p.(Arg800Trp) 
















Growth Poor weight gain Delayed Normal Short stature Normal 
Developmental 
delay 
Normal Cognitive delay, 
autism 






19th % (3.5y) 5th % (14y) Normal Microcephaly Normal 
Hearing Normal Hearing loss Normal Deaf Deaf 















with vaginal fistula, 
hemivertebrae 
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Table 2: Site Directed Mutator (SDM; http://marid.bioc.cam.ac.uk/sdm2/prediction) 
analysis of the impact of CAPN15 variants on protein stability. 
Variant G Stability 
p.S613L 1.85 Increased 
p.S720F 0.52 Increased 
p.R800W 0.24 Increased 
p.G969S -3.27 Reduced 
p.R1028K -1.15 Reduced 
